Ricerca avanzata

Home > Riviste > Minerva Endocrinologica > Fascicoli precedenti > Minerva Endocrinologica 2015 Dicembre;40(4) > Minerva Endocrinologica 2015 Dicembre;40(4):259-66

FASCICOLI E ARTICOLI   I PIÙ LETTI   eTOC

ULTIMO FASCICOLOMINERVA ENDOCRINOLOGICA

Rivista sulle Malattie del Sistema Endocrino

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,118

Periodicità: Trimestrale

ISSN 0391-1977

Online ISSN 1827-1634

 

Minerva Endocrinologica 2015 Dicembre;40(4):259-66

 ORIGINAL ARTICLES

Reduction in asymmetric dimethylarginine plasma levels by coenzyme Q10 supplementation in patients with type 2 diabetes mellitus

Hosseinzadeh-Attar M. J. 1, 2, Kolahdouz Mohammadi R. 1, 2, Eshraghian M. R. 3, Nakhjavani M. 4, Khorrami E. 1, 2, Ebadi M. 4, Esteghamati A. 4

1 Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran;
2 Department of Nutrition and Biochemistry, School of Public Health and Institute of Public Health Research, Tehran University of Medical Sciences, Tehran, Iran;
3 Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran;
4 Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, University of Medical Sciences, Tehran, Iran

AIM: According to many studies, supplementation with Coenzyme Q10 (CoQ10) yields beneficial results in terms of endothelial function in type 2 diabetes mellitus. Despite these promising results, data elucidating the effect of CoQ10 on plasma levels of asymmetric dimethylarginine (ADMA), as a recently discussed cardiovascular risk factor, is lacking. This study was designed to investigate the effect of CoQ10 supplementation on endothelial function, specifically by evaluating plasma ADMA levels.
METHODS: Sixty-four type 2 diabetic patients were randomly assigned to two groups; either receiving 200mg/d oral dose of CoQ10 (N.=31) or receiving placebo (N.=33) for 12 weeks. Clinical and biochemical assessments were performed before and after the trial for evaluating ADMA, serum nitrite and nitrate (NOx), hemoglobin A1c and lipid profile.
RESULTS: The intervention resulted in a significant improvement in ADMA, NOx , low-density lipoprotein and hemoglobin A1c levels in CoQ10 compared to placebo group. Interestingly, difference in changes of these parameters were also significant (P=0.01, 0.03, 0.04 and 0.03, respectively).
CONCLUSION: Supplementation with CoQ10 yields beneficial effects on ADMA levels, leading to decreased diabetic cardiovascular events.

lingua: Inglese


FULL TEXT  ESTRATTI

inizio pagina